
List of Figures

Figure 2.1	Structure of Human Uterus	16
Figure 2.2	Histology of Human Uterus	17
Figure 2.3	First Uterine Pass Effect	21
Figure 2.4	Types of Uterine Fibroids	23
Figure 2.5	Endometriosis	26
Figure 2.6	Types of Inorganic Nanoparticles	38
Figure 2.7	Polymeric Micelles for Targeted Drug Delivery	39
Figure 2.8	Structure of Dendrimers	40
Figure 2.9	Structure of Carbon Nanotubes	41
Figure 2.10	Structure of Liposomes	43
Figure 2.11	Intra Vaginal Rings	50
Figure 2.12	Matrix and Reservoir Type Intra Vaginal Rings	53
Figure 2.13	Different Types of Ring Inserts	54
Figure 3.1	Calibration Plot of LA in distilled water by UV-Spectrophotometry	99
Figure 3.2	Overlay Plot of LA in distilled water at 279 nm by UV-Spectrophotometry	99
Figure 3.3	Calibration Plot of LA in SVF pH 4.2 by UV-Spectrophotometry	101
Figure 3.4	Overlay Plot of LA in SVF at 280 nm by UV-Spectrophotometry	101
Figure 3.5	Calibration Plot of LA in Rabbit Serum by LCMS-MS	105
Figure 3.6	Chromatograms of calibration plot of LA showing retention time of 3.72-3.78 min	106
Figure 3.7	Calibration Plot of RLX in Methanol: Chloroform (1:9) by UV-Spectrophotometry	108
Figure 3.8	Overlay Plot of RLX in Methanol: Chloroform (1:9) by UV-Spectrophotometry	108
Figure 3.9	Calibration Plot of RLX in SVF by UV-Spectrophotometry	110
Figure 3.10	Overlay Plot of RLX in SVF by UV-Spectrophotometry	110
Figure 3.11	Calibration Plot of RLX in Rabbit Serum by LCMS-MS	115

Figure 3.12	Chromatograms of calibration plot of RLX showing retention time of 1.68-1.79 min	116
Figure 3.13	Calibration Plot of LA in SVF pH 4.2 by UV-Spectrophotometry for simultaneous estimation method	119
Figure 3.14	Calibration Plot of RLX in SVF pH 4.2 by UV-Spectrophotometry for simultaneous estimation method	119
Figure 4.1	Types of Preformulation Studies	124
Figure 4.2	FTIR Spectrum of Leuprolide acetate	128
Figure 4.3	DSC Thermogram of Leuprolide acetate	128
Figure 4.4	FTIR Spectrum of Leuprolide acetate with excipients	129
Figure 4.5	DSC Thermogram of Leuprolide acetate with excipients	130
Figure 4.6	FTIR Spectrum of Raloxifene Hydrochloride	131
Figure 4.7	DSC Thermogram of Raloxifene Hydrochloride	132
Figure 4.8	FTIR Spectrum of Raloxifene Hydrochloride with excipients	133
Figure 4.9	DSC Thermogram of Raloxifene Hydrochloride with excipients	134
Figure 4.10	Microscopic view of Liposomal vesicles	135
Figure 5.1	Response Surface Plot for showing the effect of independent variables on Vesicle size of RLX-Liposomes	147
Figure 5.2	Bubble plot to study the effect of independent factors on vesicle size of RLX-Liposomes	147
Figure 5.3	Bubble plot showing the effect of independent variables on % EE of RLX-Liposomes	149
Figure 5.4	Response Surface Plot for showing the effect of independent variables on % EE of RLX-Liposomes	150
Figure 5.5	Desirability Plot for Optimization of RLX-liposomes	151
Figure 5.6	Response Surface Plot for showing the effect of independent variables on Vesicle size of LA-Liposomes	156
Figure 5.7	Bubble plot showing the effect of independent variables on Vesicle size of LA-Liposomes	157
Figure 5.8	Response Surface Plot for showing the effect of	158

	independent variables on % EE of LA-Liposomes	
Figure 5.9	Bubble plot showing the effect of independent variables on % EE of LA-Liposomes	158
Figure 5.10	Bubble plot to show the relationship between Vesicle size and % EE of LA-Liposomes	159
Figure 5.11	Desirability Plot for Optimization of LA-liposomes	160
Figure 5.12	Response Surface Plot for showing the effect of independent variables on Vesicle size of dual drug loaded liposomes	165
Figure 5.13	Bubble plot showing the effect of independent variables on vesicle size of dual drug loaded liposomes	166
Figure 5.14	Response Surface Plot for showing the effect of independent variables on % EE of RLX in dual drug loaded liposomes	167
Figure 5.15	Response Surface Plot for showing the effect of independent variables on % EE of LA in dual drug loaded liposomes	167
Figure 5.16	Bubble plot showing the effect of independent variables on % EE of RLX in dual drugs loaded liposomes	168
Figure 5.17	Bubble plot showing the effect of independent variables on % EE of LA in dual drugs loaded liposomes	169
Figure 5.18	Bubble plot to show the relationship between Vesicle size and % EE of LA and RLX in dual drug entrapped liposomes	170
Figure 5.19	Bubble plot to show the relationship between % EE of LA and % EE of RLX in dual drug entrapped liposomes	171
Figure 5.20	Desirability Plot for Optimization of Dual drug (RLX and LA) loaded liposomes	172
Figure 6.1	Vesicle size of optimized batch of RLX-Liposomes	179
Figure 6.2	Vesicle size of optimized batch of LA-Liposomes	180
Figure 6.3	Vesicle size of optimized batch of RLX-LA Liposomes	180
Figure 6.4	Zeta potential of Optimized batch of RLX loaded Liposomes	182
Figure 6.5	Zeta potential of Optimized batch of LA loaded Liposomes	182

Figure 6.6	Zeta potential of Optimized batch of dual drug loaded Liposomes	183
Figure 6.7	TEM images of RLX loaded liposomes	185
Figure 6.8	TEM image of LA loaded liposomes	186
Figure 6.9	TEM image of dual drug (RLX-LA) loaded liposomes	186
Figure 6.10	SEM image of RLX loaded liposomes	187
Figure 6.11	SEM image of LA loaded liposomes	187
Figure 6.12	SEM image of dual drug (RLX-LA) loaded liposomes	188
Figure 6.13	In Vitro Drug release profile of RLX loaded optimized liposomes	190
Figure 6.14	In Vitro Drug release profile of LA loaded optimized liposomes	191
Figure 6.15	In Vitro Drug release profile of Dual Drug loaded optimized liposomes	192
Figure 6.16	In Vitro drug release profile of RLX-liposomes from IVR	193
Figure 6.17	In Vitro drug release profile of LA-liposomes from IVR	194
Figure 6.18	In Vitro drug release profile of dual drug entrapped liposomes from IVR	195
Figure 7.1	Vaginal tissue treated with Phosphate Buffer pH 4.5 (negative control) for A) One week B) Two weeks	199
Figure 7.2	Vaginal tissue treated with Isopropyl Alcohol (positive control) for A) One week B) Two weeks	200
Figure 7.3	Vaginal tissue treated with standard RLX for A) One week B) Two weeks	200
Figure 7.4	Vaginal tissue treated with standard LA for A) One week B) Two weeks	201
Figure 7.5	Vaginal tissue treated with RLX-Liposomes for A) One week B) Two weeks	201
Figure 7.6	Vaginal tissue treated with LA-Liposomes for A) One week B) Two weeks	202
Figure 7.7	Vaginal tissue treated with RLX-LA-Liposomes for A) One week B) Two weeks	202

Figure 8.1	Schematic presentation of principle for cell cycle analysis using DNA intercalating fluorescence probe in flow cytometry	206
Figure 8.2	Cytotoxicity of different concentrations of Std RLX and RLX Liposomes at A) 12 hours B) 24 hours C) 48 hours	209-10
Figure 8.3	IC50 values of Std. RLX and RLX-Liposomes in MCF-7 cell line at 12 hours, 24 hours and 48 hours	212
Figure 8.4	Cytotoxicity of different concentrations of Std LA and LA Liposomes at A) 12 hours B) 24 hours C) 48 hours	213-14
Figure 8.5	IC50 values of Std. LA and LA-Liposomes in MCF-7 cell line at 12 hours, 24 hours and 48 hours	215
Figure 8.6	Cytotoxicity comparison of RLX-LA Liposomes, RLX Liposomes and LA Liposomes at A) 12 hours B) 24 hours C) 48 hours	216-17
Figure 8.7	IC50 values of RLX-LA-Liposomes in MCF-7 cell line at 12 hours, 24 hours and 48 hours	218
Figure 8.8	Apoptosis estimation in MCF7 cell line after exposure of standard drugs and liposomal formulations at 12 hours and 24 hours	219-20
Figure 8.9	Effect of UT (Control), Std. RLX, RLX-Liposomes, Std LA, LA-Liposomes, RLX-LA Liposomes exposure on cell cycle distribution in MCF7 cells using FACS as an estimation technique	222
Figure 9.1	DTPA challenge test of A) RLX- ^{99m} Tc complex B) LA- ^{99m} Tc complex	235-36
Figure 9.2	Uterine targeting efficiency of RLX loaded liposomes vs. plain drug	238
Figure 9.3	Gamma Scintigraphy of Rabbit, which was administered ^{99m} Tc-Labeled Raloxifene Hydrochloride loaded liposomes via Vaginal route, imaged after A) 0.25 hour; B) 1 hour C) 2 hours D) 4 hours E) 18 hours F) 24 hours	239
Figure 9.4	Gamma Scintigraphy of Rabbit, which was administered	240

	99mTc-Labeled Raloxifene Hydrochloride plain drug via vaginal route, imaged after A) 0.25 hour; B) 1 hour C) 2 hours D) 4 hours E) 18 hours F) 24 hours	
Figure 9.5	Uterine targeting efficiency of LA loaded liposomes vs. plain drug	242
Figure 9.6	Gamma Scintigraphy of Rabbit, which was administered 99mTc-Labeled Leuprolide Acetate loaded liposomes via vaginal route, imaged after A) 0.25 hour; B) 1 hour C) 2 hours D) 4 hours E) 18 hours F) 24 hours	243
Figure 9.7	Gamma Scintigraphy of Rabbit, which was administered 99mTc-Labeled Leuprolide Acetate plain drug via vaginal route, imaged after A) 0.25 hour; B) 1 hour C) 2 hours D) 4 hours E) 18 hours F) 24 hours	244
Figure 10.1	Relationship of Pharmacokinetics and Pharmacodynamics	247
Figure 10.2	Rabbit with dorsal side shaved for ultrasonography	250
Figure 10.3	Ultrasonography procedure of the rabbits	251
Figure 10.4	Ultrasonography of rabbit uterus depicting clear uterine lumen (Normal/Negative control)	252
Figure 10.5	Ultrasonography of rabbit uterus showing uterine fibroid in the lumen (Positive control)	253
Figure 10.6	Ultrasonography of Rabbit administered with Leuprolide liposomal formulation after A) 15 days B) 30 days; Rabbit administered with Raloxifene liposomal formulation after C) 15 days D) 30 days; Rabbit administered with dual drug loaded liposomal formulation after E) 15 days E) 30 days	255
Figure 10.7	Chromatograms of LA in rabbit plasma at various time intervals	257
Figure 10.8	Chromatograms of RLX in rabbit plasma at various time intervals	258